title: Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer.
abstract: OBJECTIVE
  To compare the efficacy and safety of paclitaxel combined with fluorouracil plus cisplatin (PCF), and oxaliplatin combined with fluorouracil plus leucovorin (FOLFOX-4) regimens for advanced gastric cancer (AGC).
  
  
  METHODS
  Ninety-four patients with AGC were randomly assigned to receive paclitaxel (50 mg/m(2) iv) on days 1, 8 and 15, cisplatin (20 mg/m(2) iv) and fluorouracil (750 mg/m(2) iv) on days 1-5, or oxaliplatin (85 mg/m(2) iv) and leucovorin (200 mg/m(2) iv) on day 1, followed by bolus fluorouracil (400 mg/m(2) iv) and fluorouracil (600 mg/m(2) iv) on days 1 and 2. The primary end point was the 1-year survival time.
  
  
  RESULTS
  The overall response rate (ORR) of the patients was 48.0% and 45.5% to PCF and FOLFOX-4, respectively. The disease control rate (DCR) of PCF and FOLFOX-4 was 82.0% and 81.8%, respectively. The median survival times (MSTs) of the patients were 10.8 and 9.9 mo, respectively, after treatment with PCF and FOLFOX-4. The 1-year survival rate of the patients was 36.0% and 34.1%, respectively, after treatment with PCF and FOLFOX-4. No significant difference was observed in ORR, DCR, MST or 1-year survival rate between the two groups. The most common adverse events were anemia, nausea and vomiting, and grade 3/4 alopecia in PCF treatment group, and anemia, grade 1/2 neurotoxic effect and grade 3/4 neutropenia in FOLFOX-4 treatment group.
  
  
  CONCLUSIONS
  Patients with AGC have a similar response rate to PCF and FOLFOX-4 regimens with a similar survival rate. The PCF and FOLFOX-4 regimens are efficacious and tolerable as a promising therapy for AGC.
authors: Department of Oncology, the Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu Province, China.
authors: Xiao-Dong
authors: XD
authors: Li
authors: Hua
authors: H
authors: Shen
authors: Jing-Ting
authors: JT
authors: Jiang
authors: Han-Ze
authors: HZ
authors: Zhang
authors: Xiao
authors: X
authors: Zheng
authors: Yong-Qian
authors: YQ
authors: Shu
authors: Chang-Ping
authors: CP
authors: Wu
mesh_terms: D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D017239:Paclitaxel / Q000627:therapeutic use*; D013274:Stomach Neoplasms / Q000188:drug therapy*; D015996:Survival Rate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D017239:Paclitaxel